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Context: TheA883F germlinemutation of the rearranged during transfection (RET) proto-oncogene
causes multiple endocrine neoplasia 2B. In the revised American Thyroid Association (ATA)
guidelines for the management of medullary thyroid carcinoma (MTC), the A883F mutation has
been reclassified from thehighest to the high-risk level, althoughnowell-defined risk profile for this
mutation exists.
Objective: To create a risk profile for the A883F mutation for appropriate classification among the
ATA risk levels.
Design: Retrospective analysis.
Setting: International collaboration.
Patients: Included were 13 A883F carriers.
Intervention: The intervention was thyroidectomy.
Main OutcomeMeasures: Earliest age ofMTC, regional lymph nodemetastases, distant metastases,
age-related penetrance of MTC and pheochromocytoma (PHEO), overall and disease-specific
survival, and biochemical cure rate.
Results:One and three carriers were diagnosed at age 7 to 9 years (median, 7.5 years) with a normal
thyroid and C-cell hyperplasia, respectively. Nine carriers were diagnosed with MTC at age 10 to 39
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Abbreviations: ATA, American Thyroid Association; MEN2, multiple endocrine neo-
plasia 2; MTC, medullary thyroid carcinoma; PHEO, pheochromocytoma; TNM, tumor-
node-metastasis; WorldMEN, International Workshop on Multiple Endocrine Neoplasia.
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years (median, 19 years). The earliest age of MTC, regional lymph node metastasis, and distant
metastasis was 10, 20, and 20 years, respectively. Fifty percent penetrance of MTC and PHEO was
achieved by age 19 and 34 years, respectively. Five- and 10-year survival rates (both overall and
disease specific) were 88% and 88%, respectively. Biochemical cure for MTC at latest follow-up was
achieved in 63% (five of eight carriers) with pertinent data.
Conclusions: MTC of A883F carriers seems to have a more indolent natural course compared with
that ofM918T carriers. Our results support the classification of the A883Fmutation in the ATA high-
risk level. (J Clin Endocrinol Metab 102: 2069–2074, 2017)
Multiple endocrineneoplasia2 (MEN2) is anautosomal-dominant, inherited cancer syndrome that is sub-
divided into MEN2A and MEN2B. MEN2A associates
medullary thyroid carcinoma (MTC), pheochromocytoma
(PHEO), hyperparathyroidism, cutaneous lichen amy-
loidosis, and Hirschsprung disease. MEN2B associates
MTC, PHEO, ganglioneuromatosis of the aerodigestive
tract, and facial, ophthalmologic, and skeletal abnor-
malities (1).
In 1993 and 1994, activating missense germline mu-
tations of the rearranged during transfection (RET)
proto-oncogene were discovered to cause MEN2A and
MEN2B (2–6). MEN2A is most commonly caused by
mutations of codon 634 (7), whereas MEN2B is caused
by the M918T and A883F mutation in approximately
95% and ,5% of cases, respectively (1).
Shortly after these pivotal discoveries, strong genotype-
phenotype correlations were recognized (8, 9). This
provided the basis for individual risk profiles and es-
tablishment of the American Thyroid Association
(ATA) MTC risk levels, according to the specific mu-
tations (1, 10).
In MEN2A, several risk profiles for mutations of
codon 10, 11, and 15 have been well defined (11–13).
In MEN2B, almost all published reports concern the
M918T mutation, and little is known about the ag-
gressiveness of the A883F mutation. Despite the lack of a
well-defined risk profile, the A883F mutation has been
reclassified from the highest to the high-risk level in the
revised ATA guidelines for the management of MTC (1).
We conducted an international cohort study of A883F
carriers for the purpose of creating a risk profile for
appropriate classification in the ATA risk levels.
Patients and Methods
Patients
This international retrospective cohort study included 13
unique A883F carriers from eight unrelated families.
At the International Workshop on Multiple Endocrine
Neoplasia (WorldMEN) 2014 in Vienna, Austria, the World-
MEN 2016 workshop in Utrecht, the Netherlands, and during
various other scientific meetings, all knownMEN2 centers were
asked to contribute relevant data to this study. Eleven A883F
carriers were identified.
Additionally, a systematic literature search was performed.
Of 199 unique citations, 12 reported A883F germline carriers
(14–25). The reference list of each citation was scrutinized to
uncover carriers published more than once. When this was
insufficient, an author of the concerned publication was con-
tacted for clarification. Six of the 12 citations described an
A883F carrier who had been reported previously (14–16, 19,
22, 23). The remaining six citations were found to be the
original reports of 12 A883F carriers (17, 18, 20, 21, 24, 25),
two of whom had not been identified by the inquiries at the
WorldMEN workshops. Thus, a total of 13 unique carriers
were identified and included.
Data collectionwas performed using a uniformdata sheet for
each registrant. One carrier had been lost to follow-up several
years before, and only data already published in relation to this
carrier could be retrieved (15, 18, 19).
This study was approved by the respective institutional re-
view boards for human subjects’ protection in accordance with
the ethical standards of each country and center.
Methods
The follow-up period was calculated from the date of MTC
diagnosis to the date of deathor latest follow-up.The date ofMTC
diagnosis was recorded as the date of initial thyroid surgery.
TNM (tumor-node-metastasis) staging was performed
according to the seventh edition of the American Joint Com-
mittee on Cancer Staging Manual (26).
Biochemical cure was defined as basal serum calcitonin
below the upper reference limit of the respective calcitonin
assays at latest follow-up.
Statistical analysis
Continuous variables were calculated as the median and
range. The Kaplan-Meier method was used for estimating age-
related penetrance of MTC and PHEO, overall survival, and
disease-specific survival. All analyses were performed using
Stata 14.1 (StataCorp, College Station, TX).
Results
A total of 13 carriers from eight unrelated families were
included. Demographic, clinical, surgical, and follow-up
data are shown in Table 1. De novo mutations were
recorded in five (45%) of the 11 carriers with pertinent
data.
Carriers and families originated from the United States
(four carriers from one family), United Kingdom (four
carriers from three families), France (two carriers from
one family), Germany (one carrier from one family),
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Denmark (one carrier from one family), and Australia
(one carrier from one family).
Normal/C-cell hyperplasia
Upon prophylactic thyroidectomy, carrier no. 4 was
diagnosed with a normal thyroid, and carriers no. 1 to 3
were diagnosed with C-cell hyperplasia (Table 1). Me-
dian age at diagnosis was 7.5 years (range, 7 to 9 years).
MTC
Nine carriers were diagnosed with MTC. Median age
at diagnosis was 19 years (range, 10 to 39 years).
Full TNM status at initial thyroid surgery was available
in six carriers. MTCwithout metastasis (T1-4N0M0) was
diagnosed in two carriers with a median age of 28.5 years
(range, 25 to 32 years). MTC with regional lymph node
metastasis but without distant metastasis (T1-4N1M0)
was diagnosed in three carriers with a median age of
13 years (range, 10 to 39 years). Distant metastasis
(T1-4N0M1 or T1-4N1M1) was diagnosed in one carrier
at age 28 years. However, the earliest observed age of
distant metastasis was 20 years, 10 years after initial
thyroid surgery (carrier no. 6).
Twenty-five percent, 50%, and 75% penetrance for
MTC was achieved at 10, 19, and 28 years, respectively
(Fig. 1).
Median follow-up of the nine carriers with MTC was
12 years (range, 4 to 35 years). One carrier died (as a
result of MTC) at 32 years of age after four years of
follow-up. Eight carriers were still alive at latest follow-
up. Five- and 10-year survival rates (both overall and
disease specific) were 88% and 88%, respectively.
Basal serum calcitonin at latest follow-up was avail-
able for 12 of 13 A883F carriers. Nine of the 12 (75%)
had achieved biochemical cure. Among the seven index
carriers with pertinent data, four (57%) had achieved
biochemical cure. Among the A883F carriers with MTC
and pertinent data, biochemical cure was seen in five of
eight (63%) (Table 1).
PHEO
Five of 13 (38%) carriers were diagnosed with PHEO.
Themedian age at diagnosis was 34 years (range, 11 to 44
years). Twenty-five percent, 50%, and 75% penetrance
was achieved at 23, 34, and 39 years, respectively (Fig. 1).
All PHEOs were bilateral and adrenal in location. None
were malignant. All carriers had been diagnosed with
MTC prior to PHEO. The median interval between the
Table 1. Demographic, Clinical, Surgical, and Follow-Up Data for 13 A883F Carriers
Carrier
No.
Family
No. Sex
Index
Carrier
Mucosal
Neuroma
Marfanoid
Habitus
At Initial Adrenal
Surgery At Initial Thyroid Surgery
At Latest
Follow-Up
Age, y Pathology Age, y Procedure Pathology TNMa Age, y BCb Reference
1 1 F No No No 7 TTX CCH T0N0M0 8 Yes 24
2 1 F No No No 7 TTX CCH T0N0M0 8 Yes 24
3 2 M No Yes No 8 TTX + LND CCH T0N0M0 8 Yes 17
4 1 M No Yes No 9 TTX Normal T0N0M0 10 Yes 24
5 7 F Yes Yes Yes 10 TTX MTC TxNxMx 37 Yes 21
6 6 F Yes Yes No NA 10 TTX MTC TxN0M0c 22 NA 15, 18, 19
7 4 M Yes Yes Yes 11 PHEO 10 TTX + LND MTC T1aN1bM0 19 No 25
8 5 F Yes Yes Yes 34 PHEO 13 TTX MTC T1N1M0 34 Yes 18
9 8 F Yes Yes Yes 23 PHEO 19 TTX MTC TxNxMxd 47 No 21
10 3 F Yes Yes Yes 44 PHEO 25 TTX MTC T2N0M0 60 Yes 20
11 2 F Yes Yes No 28 TTX + LND MTC T4aN1bM1 32 Noe 17
12 3 M No Yes Yes 32 TTX + LND MTC T2N0M0 37 Yes
13 1 F Yes Yes No 39 PHEO 39 TTX + LND MTC T3N1bM0 44 Yes 24
Abbreviations: BC, biochemical cure; CCH, C-cell hyperplasia; F, female; LND, lymph node dissection; M, male; NA, not available; TTX, total
thyroidectomy.
aAccording to the 7th edition of the American Joint Committee on Cancer Staging Manual.
bDefined as basal serum calcitonin lower than the upper reference limit.
cN1b and M1 (liver) at 12 and 20 years of age, respectively.
dM1 (mediastinum) at 29 years of age.
eDied as a result of MTC.
Figure 1. Age-related penetrance in 13 A883F carriers.
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diagnosis of MTC and the diagnosis of PHEO was five
years (range, 0 to 22 years).
Nonendocrine manifestations
Mucosal neuromas were shown in all but two carriers.
Only the two youngest females, age 7 years, had no visible
mucosal neuromas.Marfanoid habitus, thick eyelids, and
narrow faces were described in six of the 13 patients. Pes
cavus was diagnosed in three carriers.
Discussion
On the basis of this international retrospective cohort
study of 13 A883F carriers from eight unrelated families,
we created a risk profile for the A883F RET mutation.
Our data show that the age-related penetrance of disease
manifestations such asMTC and PHEO occur later in life
than formerly thought.
Concerning age-related penetrance for MTC in our
series, 50% penetrance of MTC in the A883F carriers
was achieved by 19 years of age (Fig. 1). This is clearly
later in life than in M918T carriers, who are grouped as
having the highest risk mutation in the recently revised
ATA guidelines; in this highest risk level, 50%penetrance
of MTC was described at age 12 years (27). More similar
to our results, the 50% penetrance for carriers of the
C634R, C634W, and C634Y mutations (classified at the
ATA high-risk level) has been reported at approximately
19, 30, and 33 years of age (12, 28). Considerably more
favorable was the age-related penetrance ofMTC in exon
10 codons 609, 611, 618, and 620 (ATA moderate-risk
level), ranging from age 34 to 44 years (Table 2) (11).
Thus, in regard to age-related penetrance for MTC, the
A883F mutation resembles the other mutations in the
ATA high-risk level.
In regard to the earliest onset of MTC, a normal
thyroid and C-cell hyperplasia without MTC were di-
agnosed in four carriers of age 7 to 9 years. The earliest
age of diagnosis of MTC, regional lymph node, and
distant metastasis was 10, 10, and 20 years, respectively.
This is distinctively later than in the ATA highest-risk
level. The earliest ages of MTC, regional, and distant
metastasis in M918T carriers (ATA highest-risk level)
have been reported at 0.17, 0.25, and 5 years of age,
respectively (29–31). For mutation carriers of codon 634
(ATA high-risk level), the corresponding ages have been
reported at 0.8, 5, and 20 years (30, 32, 33). The earliest
ages of MTC, regional metastasis, and distant metastasis
reported in carriers of mutations classified at the ATA
moderate-risk level have been reported at age 1, 6, and
6 years, respectively (34, 35). However, considerable
variability in the age of earliest onset in regard to mutated
codons and mutated amino acids has been reported in
carriers belonging to the ATA moderate-risk level cate-
gory (36). If one follows the rule of earliest onset, the
A883F mutation appears to be most appropriately
classified in the ATA high-risk or even ATA moderate-
risk level.
Biochemical cure at the latest follow-up was achieved
in 75% and 57% of our total cohort and our index
carriers with pertinent data, respectively. In a study of
M918T carriers, biochemical cure was found less fre-
quently, in 23% (10 of 44) and 17% (seven of 41) of the
total cohort and the index carriers, respectively (37).
Thus, the proportion of A883F carriers achieving bio-
chemical cure appears large compared with that of the
M918T carriers. In a recent study, biochemical cure in
C634R and C634Y carriers with MTC was seen in 58%
(32 of 55) and 63% (22 of 35), respectively (38). Cor-
respondingly, biochemical cure was achieved in 63% of
the A883F carriers with MTC. When using biochemical
cure for risk classification, the A883F cohort resembles
the high-risk level.
Five- and 10-year survival rates (both overall and
disease specific) were 88% and 88%, respectively. In a
study of 18 patients with MEN2B and MTC, all of
the 16 RET-tested patients were M918T carriers. Five-
and 10-year overall survival rates were 85% and 75%,
respectively (27). Accordingly, the overall survival of
A883F carriers seems favorable compared with that of
M918T carriers, which also justifies classification of this
mutation in the high-risk level.
PHEO was diagnosed at a median age of 34 years in
the A883F carriers. This was 12 years later than seen in
M918T carriers and eight years earlier than in exon 10
mutation carriers (11, 27). Therefore, with respect to
Table 2. Age of 50%Penetrance forMTCAccording
to RET Mutation and ATA Risk Level
ATA Risk
Level Mutation
Age at 50%
Penetrance
for MTC, y Reference
MOD C609F/G/R/S/Ya ~40 11
C611F/Y/Wa ~44 11
C618F/G/R/S/Ya ~35 11
C620F/G/R/S/Ya ~34 11
H C634R ~19 28
C634W ~30b 12
C634Y ~33 28
A883F ~19 Present study
HST M918Tc ~12d 27
Abbreviations: H, high; HST, highest; MOD, moderate.
aMutations of the given codon are pooled.
bAge-related penetrance at 52%.
cEighteen patients with MEN2B in the study. The 16 RET-tested patients
were all M918T carriers.
dCalculated using the Kaplan-Meier method from the data available in
the reference.
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PHEO, stratifying the A883F mutation in the ATA high-
risk level seems justified.
This study shares limitations that are inherent to
retrospective multinational studies of rare diseases.
Small sample sizes limiting generalization are often
seen when studying rare diseases, as in this study. To
increase sample size, carriers of different amino acid
substitutions within the same codon can be pooled
(11). To the best of our knowledge, there has only been
one report of a mutation in codon 883 other than the
A883F mutation (39). However, inclusion of patients
carrying the A883T mutation from this report was not
appropriate, given that no MEN2B phenotype was
described. The A883T mutation showed a very low
transforming activity, as demonstrated by the absence
of the MTC phenotype in heterozygous carriers. MTC
was only present in two homozygous carriers (39).
Retrospective studies are frequently associated with
missing data. However, no data were missing with
regard to key variables in this study, such as ages,
procedure, and pathology at initial thyroid surgery.
Data on status and biochemical cure at latest follow-up
were present in 89% (eight of nine) of carriers with
MTC. Full TNM status at initial thyroid surgery was
available in 67% (six of nine) of carriers with MTC.
MEN2B nonendocrine manifestations were present to
some extent in all A883F carriers, but with this small
data set, we were not able to describe if manifestations
develop later or in a more discrete variant in A883F
compared with M918T carriers.
Conclusion
MTC of A883F RET mutation carriers seems to have a
more indolent natural course compared with that of
M918T carriers. PHEO manifests later in A883F carriers
than in M918T carriers. Our results support the classifi-
cation of the A883F mutation in the ATA high-risk level.
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